Form 4: Regentis Biomaterials Director Receives Stock Grant
Insider Transaction (Form 4)
Jeff Dykan, a Director of Regentis Biomaterials Ltd., reported multiple transactions in common stock on July 9, 2026.
Summary
- Grant/award: acquired 12,500 Warrants to purchase ordinary shares on July 9, 2026; holds 12,500 after (Direct).
- Grant/award: acquired 24,826 Employee Stock Option (Right to Buy) on July 9, 2026; holds 24,826 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jeff Dykan — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-09 | Grant/award | Warrants to purchase ordinary shares | 12,500 | — | — | 12,500 |
| 2026-07-09 | Grant/award | Employee Stock Option (Right to Buy) | 24,826 | — | — | 24,826 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-09 | Grant/award (12,500 shares) |
| 2026-07-09 | Grant/award (24,826 shares) |
Keywords
insider transaction, Form 4, RGNT, REGENTIS BIOMATERIALS LTD., neutral, Jeff Dykan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.